http://streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Thu, 18 Jun 2026 09:20:13 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/FDA/Longeveron+stem+cell+therapy+data+to+be+presented+at+2026+AAIC/26663848.html <p>Longeveron Inc. (NASDAQ: LGVN) announced that additional analysis of Phase 2a clinical trial data for its stem cell therapy laromestrocel in mild Alzheimer's disease has been accepted for a poster presentation at the 2026 Alzheimer's Association International Conference (AAIC), scheduled for July 12–15, 2026, in London and online.</p> <p>The presentation is set for Monday, July 13, 2026, from 7:30 a.m. to 4:15 p.m. BST in the exhibit hall, under the session titled "Drug Development: Human."</p> <p>The data stems from Longeveron's CLEAR MIND Phase 2a clinical trial. Results from that trial were previously published in the peer-reviewed journal <em>Nature Medicine</em> in March 2025.</p> <p>Laromestrocel http://www.streetinsider.com/FDA/Longeveron+stem+cell+therapy+data+to+be+presented+at+2026+AAIC/26663848.html Thu, 18 Jun 2026 09:20:13 -0400 LGVN LGVNR O.49866458 http://www.streetinsider.com/FDA/Longeveron+stem+cell+therapy+data+to+be+presented+at+2026+AAIC/26663848.html <p>Longeveron Inc. (NASDAQ: LGVN) announced that additional analysis of Phase 2a clinical trial data for its stem cell therapy laromestrocel in mild Alzheimer's disease has been accepted for a poster presentation at the 2026 Alzheimer's Association International Conference (AAIC), scheduled for July 12–15, 2026, in London and online.</p> <p>The presentation is set for Monday, July 13, 2026, from 7:30 a.m. to 4:15 p.m. BST in the exhibit hall, under the session titled "Drug Development: Human."</p> <p>The data stems from Longeveron's CLEAR MIND Phase 2a clinical trial. Results from that trial were previously published in the peer-reviewed journal <em>Nature Medicine</em> in March 2025.</p> <p>Laromestrocel http://www.streetinsider.com/FDA/Longeveron+stem+cell+therapy+data+to+be+presented+at+2026+AAIC/26663848.html Thu, 18 Jun 2026 09:20:13 -0400 LGVN LGVNR O.49866458 http://www.streetinsider.com/FDA/Longeveron+stem+cell+therapy+data+to+be+presented+at+2026+AAIC/26663848.html <p>Longeveron Inc. (NASDAQ: LGVN) announced that additional analysis of Phase 2a clinical trial data for its stem cell therapy laromestrocel in mild Alzheimer's disease has been accepted for a poster presentation at the 2026 Alzheimer's Association International Conference (AAIC), scheduled for July 12–15, 2026, in London and online.</p> <p>The presentation is set for Monday, July 13, 2026, from 7:30 a.m. to 4:15 p.m. BST in the exhibit hall, under the session titled "Drug Development: Human."</p> <p>The data stems from Longeveron's CLEAR MIND Phase 2a clinical trial. Results from that trial were previously published in the peer-reviewed journal <em>Nature Medicine</em> in March 2025.</p> <p>Laromestrocel http://www.streetinsider.com/FDA/Longeveron+stem+cell+therapy+data+to+be+presented+at+2026+AAIC/26663848.html Thu, 18 Jun 2026 09:20:13 -0400 LGVN LGVNR O.49866458 http://www.streetinsider.com/Press+Releases/New+Phase+2a+Clinical+Data+Analysis+of+Stem+Cell+Therapy+Laromestrocel+in+Mild+Alzheimer%E2%80%99s+Disease+Accepted+for+Poster+Presentation+at+the+2026+Alzheimer%E2%80%99s+Association+International+Conference+%28AA/26663845.html <p align="justify">MIAMI, June 18, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=pAPIPPmLyNqv04NOph-4EG2o7_LKgGgCQyNP2BSU5kZe1ZRLEmswXxcYATAP8fbT-43NVj34cmN1ZL1iFNmE56yX5JOUagskPnz2F-3Osak=" rel="nofollow" target="_blank">Longeveron Inc.</a> (NASDAQ: LGVN), a clinical stage biotechnology company developing cellular therapy for life-threatening, rare pediatric and chronic aging-related conditions, today announced that additional analysis of data from the Phase 2a clinical trial evaluating its stem cell therapy <a target="_blank" href="https://www.globenewswire.com/Tracker?data=5i-31qv-I_E9hRL7y73oMRk1E_jgOBWYmPiNYoNnQdRtOIzc5eyBfWIBEs5C5lIvcZtDmzmEQxCnPklj2TKvwMq2rXJ0qiYrwNAz9H8NSCs=" rel="nofollow" target="_blank">laromestrocel</a> in mild <a target="_blank" href="https://www.globenewswire.com/Tracker?data=qfE9EZMjs79GXexINc9F46eJKRlAMZyYYbi6och78rOuG4KAPLAcVn3Nh-WIpI069eAPlTbyJjCFTq29WHzwiDgpkYmLpqB9yQuBwySigVj1e8sxOCnbQbwYHKS3C7ut9LZnWId08jcfOhQ6pPWVAA==" rel="nofollow" target="_blank">Alzheimer’s disease</a> has been accepted for Poster Presentation at the <a target="_blank" href="https://www.globenewswire.com/Tracker?data=QXPkaVxBwq6Jn_3ByK8GWm71L2SoRi7cbdqLYI4JjRR4w44LZsxJ0lvndO4JAW9YGIliGgJ8V_qr510Mzay8S3W6uFx_Go1Rm83zNsfWV-ezi7p0iJTcvc6oPW4swWYgNTGbgAFg7A5fPk5ONxAkKjEOEA0j6h7iV-ity3KJO-c=" rel="nofollow" target="_blank">2026 Alzheimer’s Association International Conference® (AAIC®)</a>, to be held July 12-15, 2026 in London, United Kingdom and online.</p> <table style="border-collapse: collapse; width:100%; border-collapse:collapse http://www.streetinsider.com/Press+Releases/New+Phase+2a+Clinical+Data+Analysis+of+Stem+Cell+Therapy+Laromestrocel+in+Mild+Alzheimer%E2%80%99s+Disease+Accepted+for+Poster+Presentation+at+the+2026+Alzheimer%E2%80%99s+Association+International+Conference+%28AA/26663845.html Thu, 18 Jun 2026 09:20:00 -0400 LGVN LGVNR O.49866458 http://www.streetinsider.com/Press+Releases/New+Phase+2a+Clinical+Data+Analysis+of+Stem+Cell+Therapy+Laromestrocel+in+Mild+Alzheimer%E2%80%99s+Disease+Accepted+for+Poster+Presentation+at+the+2026+Alzheimer%E2%80%99s+Association+International+Conference+%28AA/26663845.html <p align="justify">MIAMI, June 18, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=pAPIPPmLyNqv04NOph-4EG2o7_LKgGgCQyNP2BSU5kZe1ZRLEmswXxcYATAP8fbT-43NVj34cmN1ZL1iFNmE56yX5JOUagskPnz2F-3Osak=" rel="nofollow" target="_blank">Longeveron Inc.</a> (NASDAQ: LGVN), a clinical stage biotechnology company developing cellular therapy for life-threatening, rare pediatric and chronic aging-related conditions, today announced that additional analysis of data from the Phase 2a clinical trial evaluating its stem cell therapy <a target="_blank" href="https://www.globenewswire.com/Tracker?data=5i-31qv-I_E9hRL7y73oMRk1E_jgOBWYmPiNYoNnQdRtOIzc5eyBfWIBEs5C5lIvcZtDmzmEQxCnPklj2TKvwMq2rXJ0qiYrwNAz9H8NSCs=" rel="nofollow" target="_blank">laromestrocel</a> in mild <a target="_blank" href="https://www.globenewswire.com/Tracker?data=qfE9EZMjs79GXexINc9F46eJKRlAMZyYYbi6och78rOuG4KAPLAcVn3Nh-WIpI069eAPlTbyJjCFTq29WHzwiDgpkYmLpqB9yQuBwySigVj1e8sxOCnbQbwYHKS3C7ut9LZnWId08jcfOhQ6pPWVAA==" rel="nofollow" target="_blank">Alzheimer’s disease</a> has been accepted for Poster Presentation at the <a target="_blank" href="https://www.globenewswire.com/Tracker?data=QXPkaVxBwq6Jn_3ByK8GWm71L2SoRi7cbdqLYI4JjRR4w44LZsxJ0lvndO4JAW9YGIliGgJ8V_qr510Mzay8S3W6uFx_Go1Rm83zNsfWV-ezi7p0iJTcvc6oPW4swWYgNTGbgAFg7A5fPk5ONxAkKjEOEA0j6h7iV-ity3KJO-c=" rel="nofollow" target="_blank">2026 Alzheimer’s Association International Conference® (AAIC®)</a>, to be held July 12-15, 2026 in London, United Kingdom and online.</p> <table style="border-collapse: collapse; width:100%; border-collapse:collapse http://www.streetinsider.com/Press+Releases/New+Phase+2a+Clinical+Data+Analysis+of+Stem+Cell+Therapy+Laromestrocel+in+Mild+Alzheimer%E2%80%99s+Disease+Accepted+for+Poster+Presentation+at+the+2026+Alzheimer%E2%80%99s+Association+International+Conference+%28AA/26663845.html Thu, 18 Jun 2026 09:20:00 -0400 LGVN LGVNR O.49866458 http://www.streetinsider.com/Press+Releases/New+Phase+2a+Clinical+Data+Analysis+of+Stem+Cell+Therapy+Laromestrocel+in+Mild+Alzheimer%E2%80%99s+Disease+Accepted+for+Poster+Presentation+at+the+2026+Alzheimer%E2%80%99s+Association+International+Conference+%28AA/26663845.html <p align="justify">MIAMI, June 18, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=pAPIPPmLyNqv04NOph-4EG2o7_LKgGgCQyNP2BSU5kZe1ZRLEmswXxcYATAP8fbT-43NVj34cmN1ZL1iFNmE56yX5JOUagskPnz2F-3Osak=" rel="nofollow" target="_blank">Longeveron Inc.</a> (NASDAQ: LGVN), a clinical stage biotechnology company developing cellular therapy for life-threatening, rare pediatric and chronic aging-related conditions, today announced that additional analysis of data from the Phase 2a clinical trial evaluating its stem cell therapy <a target="_blank" href="https://www.globenewswire.com/Tracker?data=5i-31qv-I_E9hRL7y73oMRk1E_jgOBWYmPiNYoNnQdRtOIzc5eyBfWIBEs5C5lIvcZtDmzmEQxCnPklj2TKvwMq2rXJ0qiYrwNAz9H8NSCs=" rel="nofollow" target="_blank">laromestrocel</a> in mild <a target="_blank" href="https://www.globenewswire.com/Tracker?data=qfE9EZMjs79GXexINc9F46eJKRlAMZyYYbi6och78rOuG4KAPLAcVn3Nh-WIpI069eAPlTbyJjCFTq29WHzwiDgpkYmLpqB9yQuBwySigVj1e8sxOCnbQbwYHKS3C7ut9LZnWId08jcfOhQ6pPWVAA==" rel="nofollow" target="_blank">Alzheimer’s disease</a> has been accepted for Poster Presentation at the <a target="_blank" href="https://www.globenewswire.com/Tracker?data=QXPkaVxBwq6Jn_3ByK8GWm71L2SoRi7cbdqLYI4JjRR4w44LZsxJ0lvndO4JAW9YGIliGgJ8V_qr510Mzay8S3W6uFx_Go1Rm83zNsfWV-ezi7p0iJTcvc6oPW4swWYgNTGbgAFg7A5fPk5ONxAkKjEOEA0j6h7iV-ity3KJO-c=" rel="nofollow" target="_blank">2026 Alzheimer’s Association International Conference® (AAIC®)</a>, to be held July 12-15, 2026 in London, United Kingdom and online.</p> <table style="border-collapse: collapse; width:100%; border-collapse:collapse http://www.streetinsider.com/Press+Releases/New+Phase+2a+Clinical+Data+Analysis+of+Stem+Cell+Therapy+Laromestrocel+in+Mild+Alzheimer%E2%80%99s+Disease+Accepted+for+Poster+Presentation+at+the+2026+Alzheimer%E2%80%99s+Association+International+Conference+%28AA/26663845.html Thu, 18 Jun 2026 09:20:00 -0400 LGVN LGVNR O.49866458 http://www.streetinsider.com/Globe+Newswire/New+Phase+2a+Clinical+Data+Analysis+of+Stem+Cell+Therapy+Laromestrocel+in+Mild+Alzheimer%E2%80%99s+Disease+Accepted+for+Poster+Presentation+at+the+2026+Alzheimer%E2%80%99s+Association+International+Conference+%28AA/26663845.html <p align="justify">MIAMI, June 18, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=pAPIPPmLyNqv04NOph-4EG2o7_LKgGgCQyNP2BSU5kZe1ZRLEmswXxcYATAP8fbT-43NVj34cmN1ZL1iFNmE56yX5JOUagskPnz2F-3Osak=" rel="nofollow" target="_blank">Longeveron Inc.</a> (NASDAQ: LGVN), a clinical stage biotechnology company developing cellular therapy for life-threatening, rare pediatric and chronic aging-related conditions, today announced that additional analysis of data from the Phase 2a clinical trial evaluating its stem cell therapy <a target="_blank" href="https://www.globenewswire.com/Tracker?data=5i-31qv-I_E9hRL7y73oMRk1E_jgOBWYmPiNYoNnQdRtOIzc5eyBfWIBEs5C5lIvcZtDmzmEQxCnPklj2TKvwMq2rXJ0qiYrwNAz9H8NSCs=" rel="nofollow" target="_blank">laromestrocel</a> in mild <a target="_blank" href="https://www.globenewswire.com/Tracker?data=qfE9EZMjs79GXexINc9F46eJKRlAMZyYYbi6och78rOuG4KAPLAcVn3Nh-WIpI069eAPlTbyJjCFTq29WHzwiDgpkYmLpqB9yQuBwySigVj1e8sxOCnbQbwYHKS3C7ut9LZnWId08jcfOhQ6pPWVAA==" rel="nofollow" target="_blank">Alzheimer’s disease</a> has been accepted for Poster Presentation at the <a target="_blank" href="https://www.globenewswire.com/Tracker?data=QXPkaVxBwq6Jn_3ByK8GWm71L2SoRi7cbdqLYI4JjRR4w44LZsxJ0lvndO4JAW9YGIliGgJ8V_qr510Mzay8S3W6uFx_Go1Rm83zNsfWV-ezi7p0iJTcvc6oPW4swWYgNTGbgAFg7A5fPk5ONxAkKjEOEA0j6h7iV-ity3KJO-c=" rel="nofollow" target="_blank">2026 Alzheimer’s Association International Conference® (AAIC®)</a>, to be held July 12-15, 2026 in London, United Kingdom and online.</p> <table style="border-collapse: collapse; width:100%; border-collapse:collapse http://www.streetinsider.com/Globe+Newswire/New+Phase+2a+Clinical+Data+Analysis+of+Stem+Cell+Therapy+Laromestrocel+in+Mild+Alzheimer%E2%80%99s+Disease+Accepted+for+Poster+Presentation+at+the+2026+Alzheimer%E2%80%99s+Association+International+Conference+%28AA/26663845.html Thu, 18 Jun 2026 09:20:00 -0400 LGVN LGVNR O.49866458 http://www.streetinsider.com/Globe+Newswire/New+Phase+2a+Clinical+Data+Analysis+of+Stem+Cell+Therapy+Laromestrocel+in+Mild+Alzheimer%E2%80%99s+Disease+Accepted+for+Poster+Presentation+at+the+2026+Alzheimer%E2%80%99s+Association+International+Conference+%28AA/26663845.html <p align="justify">MIAMI, June 18, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=pAPIPPmLyNqv04NOph-4EG2o7_LKgGgCQyNP2BSU5kZe1ZRLEmswXxcYATAP8fbT-43NVj34cmN1ZL1iFNmE56yX5JOUagskPnz2F-3Osak=" rel="nofollow" target="_blank">Longeveron Inc.</a> (NASDAQ: LGVN), a clinical stage biotechnology company developing cellular therapy for life-threatening, rare pediatric and chronic aging-related conditions, today announced that additional analysis of data from the Phase 2a clinical trial evaluating its stem cell therapy <a target="_blank" href="https://www.globenewswire.com/Tracker?data=5i-31qv-I_E9hRL7y73oMRk1E_jgOBWYmPiNYoNnQdRtOIzc5eyBfWIBEs5C5lIvcZtDmzmEQxCnPklj2TKvwMq2rXJ0qiYrwNAz9H8NSCs=" rel="nofollow" target="_blank">laromestrocel</a> in mild <a target="_blank" href="https://www.globenewswire.com/Tracker?data=qfE9EZMjs79GXexINc9F46eJKRlAMZyYYbi6och78rOuG4KAPLAcVn3Nh-WIpI069eAPlTbyJjCFTq29WHzwiDgpkYmLpqB9yQuBwySigVj1e8sxOCnbQbwYHKS3C7ut9LZnWId08jcfOhQ6pPWVAA==" rel="nofollow" target="_blank">Alzheimer’s disease</a> has been accepted for Poster Presentation at the <a target="_blank" href="https://www.globenewswire.com/Tracker?data=QXPkaVxBwq6Jn_3ByK8GWm71L2SoRi7cbdqLYI4JjRR4w44LZsxJ0lvndO4JAW9YGIliGgJ8V_qr510Mzay8S3W6uFx_Go1Rm83zNsfWV-ezi7p0iJTcvc6oPW4swWYgNTGbgAFg7A5fPk5ONxAkKjEOEA0j6h7iV-ity3KJO-c=" rel="nofollow" target="_blank">2026 Alzheimer’s Association International Conference® (AAIC®)</a>, to be held July 12-15, 2026 in London, United Kingdom and online.</p> <table style="border-collapse: collapse; width:100%; border-collapse:collapse http://www.streetinsider.com/Globe+Newswire/New+Phase+2a+Clinical+Data+Analysis+of+Stem+Cell+Therapy+Laromestrocel+in+Mild+Alzheimer%E2%80%99s+Disease+Accepted+for+Poster+Presentation+at+the+2026+Alzheimer%E2%80%99s+Association+International+Conference+%28AA/26663845.html Thu, 18 Jun 2026 09:20:00 -0400 LGVN LGVNR O.49866458 http://www.streetinsider.com/Globe+Newswire/New+Phase+2a+Clinical+Data+Analysis+of+Stem+Cell+Therapy+Laromestrocel+in+Mild+Alzheimer%E2%80%99s+Disease+Accepted+for+Poster+Presentation+at+the+2026+Alzheimer%E2%80%99s+Association+International+Conference+%28AA/26663845.html <p align="justify">MIAMI, June 18, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=pAPIPPmLyNqv04NOph-4EG2o7_LKgGgCQyNP2BSU5kZe1ZRLEmswXxcYATAP8fbT-43NVj34cmN1ZL1iFNmE56yX5JOUagskPnz2F-3Osak=" rel="nofollow" target="_blank">Longeveron Inc.</a> (NASDAQ: LGVN), a clinical stage biotechnology company developing cellular therapy for life-threatening, rare pediatric and chronic aging-related conditions, today announced that additional analysis of data from the Phase 2a clinical trial evaluating its stem cell therapy <a target="_blank" href="https://www.globenewswire.com/Tracker?data=5i-31qv-I_E9hRL7y73oMRk1E_jgOBWYmPiNYoNnQdRtOIzc5eyBfWIBEs5C5lIvcZtDmzmEQxCnPklj2TKvwMq2rXJ0qiYrwNAz9H8NSCs=" rel="nofollow" target="_blank">laromestrocel</a> in mild <a target="_blank" href="https://www.globenewswire.com/Tracker?data=qfE9EZMjs79GXexINc9F46eJKRlAMZyYYbi6och78rOuG4KAPLAcVn3Nh-WIpI069eAPlTbyJjCFTq29WHzwiDgpkYmLpqB9yQuBwySigVj1e8sxOCnbQbwYHKS3C7ut9LZnWId08jcfOhQ6pPWVAA==" rel="nofollow" target="_blank">Alzheimer’s disease</a> has been accepted for Poster Presentation at the <a target="_blank" href="https://www.globenewswire.com/Tracker?data=QXPkaVxBwq6Jn_3ByK8GWm71L2SoRi7cbdqLYI4JjRR4w44LZsxJ0lvndO4JAW9YGIliGgJ8V_qr510Mzay8S3W6uFx_Go1Rm83zNsfWV-ezi7p0iJTcvc6oPW4swWYgNTGbgAFg7A5fPk5ONxAkKjEOEA0j6h7iV-ity3KJO-c=" rel="nofollow" target="_blank">2026 Alzheimer’s Association International Conference® (AAIC®)</a>, to be held July 12-15, 2026 in London, United Kingdom and online.</p> <table style="border-collapse: collapse; width:100%; border-collapse:collapse http://www.streetinsider.com/Globe+Newswire/New+Phase+2a+Clinical+Data+Analysis+of+Stem+Cell+Therapy+Laromestrocel+in+Mild+Alzheimer%E2%80%99s+Disease+Accepted+for+Poster+Presentation+at+the+2026+Alzheimer%E2%80%99s+Association+International+Conference+%28AA/26663845.html Thu, 18 Jun 2026 09:20:00 -0400 LGVN LGVNR O.49866458 http://www.streetinsider.com/FDA/Longeveron+receives+SME+status+from+European+Medicines+Agency/26621609.html <p>Longeveron Inc. (NASDAQ: LGVN) announced it has received Small or Medium-sized Enterprise status from the European Medicines Agency, according to a company statement.</p> <p>The SME designation provides companies with access to scientific advice, protocol assistance, and training from dedicated EMA personnel during clinical development. Companies with this status can engage in early dialogue with EMA teams to discuss regulatory strategy and receive reduced administrative fees throughout the development process.</p> <p>The EMA reported that SME designation has improved success rates for regulatory approvals. The success rate for SME marketing authorization applications for human medicines reached 89% in 2020, more than doubling previous rates. http://www.streetinsider.com/FDA/Longeveron+receives+SME+status+from+European+Medicines+Agency/26621609.html Tue, 09 Jun 2026 09:20:13 -0400 A.31066700 LGVN LGVNR O.22422661 O.49866458 http://www.streetinsider.com/FDA/Longeveron+receives+SME+status+from+European+Medicines+Agency/26621609.html <p>Longeveron Inc. (NASDAQ: LGVN) announced it has received Small or Medium-sized Enterprise status from the European Medicines Agency, according to a company statement.</p> <p>The SME designation provides companies with access to scientific advice, protocol assistance, and training from dedicated EMA personnel during clinical development. Companies with this status can engage in early dialogue with EMA teams to discuss regulatory strategy and receive reduced administrative fees throughout the development process.</p> <p>The EMA reported that SME designation has improved success rates for regulatory approvals. The success rate for SME marketing authorization applications for human medicines reached 89% in 2020, more than doubling previous rates. http://www.streetinsider.com/FDA/Longeveron+receives+SME+status+from+European+Medicines+Agency/26621609.html Tue, 09 Jun 2026 09:20:13 -0400 A.31066700 LGVN LGVNR O.22422661 O.49866458 http://www.streetinsider.com/FDA/Longeveron+receives+SME+status+from+European+Medicines+Agency/26621609.html <p>Longeveron Inc. (NASDAQ: LGVN) announced it has received Small or Medium-sized Enterprise status from the European Medicines Agency, according to a company statement.</p> <p>The SME designation provides companies with access to scientific advice, protocol assistance, and training from dedicated EMA personnel during clinical development. Companies with this status can engage in early dialogue with EMA teams to discuss regulatory strategy and receive reduced administrative fees throughout the development process.</p> <p>The EMA reported that SME designation has improved success rates for regulatory approvals. The success rate for SME marketing authorization applications for human medicines reached 89% in 2020, more than doubling previous rates. http://www.streetinsider.com/FDA/Longeveron+receives+SME+status+from+European+Medicines+Agency/26621609.html Tue, 09 Jun 2026 09:20:13 -0400 A.31066700 LGVN LGVNR O.22422661 O.49866458 http://www.streetinsider.com/FDA/Longeveron+receives+SME+status+from+European+Medicines+Agency/26621609.html <p>Longeveron Inc. (NASDAQ: LGVN) announced it has received Small or Medium-sized Enterprise status from the European Medicines Agency, according to a company statement.</p> <p>The SME designation provides companies with access to scientific advice, protocol assistance, and training from dedicated EMA personnel during clinical development. Companies with this status can engage in early dialogue with EMA teams to discuss regulatory strategy and receive reduced administrative fees throughout the development process.</p> <p>The EMA reported that SME designation has improved success rates for regulatory approvals. The success rate for SME marketing authorization applications for human medicines reached 89% in 2020, more than doubling previous rates. http://www.streetinsider.com/FDA/Longeveron+receives+SME+status+from+European+Medicines+Agency/26621609.html Tue, 09 Jun 2026 09:20:13 -0400 A.31066700 LGVN LGVNR O.22422661 O.49866458 http://www.streetinsider.com/FDA/Longeveron+receives+SME+status+from+European+Medicines+Agency/26621609.html <p>Longeveron Inc. (NASDAQ: LGVN) announced it has received Small or Medium-sized Enterprise status from the European Medicines Agency, according to a company statement.</p> <p>The SME designation provides companies with access to scientific advice, protocol assistance, and training from dedicated EMA personnel during clinical development. Companies with this status can engage in early dialogue with EMA teams to discuss regulatory strategy and receive reduced administrative fees throughout the development process.</p> <p>The EMA reported that SME designation has improved success rates for regulatory approvals. The success rate for SME marketing authorization applications for human medicines reached 89% in 2020, more than doubling previous rates. http://www.streetinsider.com/FDA/Longeveron+receives+SME+status+from+European+Medicines+Agency/26621609.html Tue, 09 Jun 2026 09:20:13 -0400 A.31066700 LGVN LGVNR O.22422661 O.49866458 http://www.streetinsider.com/Press+Releases/Longeveron+Granted+Small+or+Medium-sized+Enterprise+%28SME%29+Status+by+the+European+Medicines+Agency+%28EMA%29/26621607.html <p align="justify">MIAMI, June 09, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=Svu60lW9WOIDqKjZTubb_1iDhmrd9w281EJUhgRzl1ltTNgv_m3Wp10qSa2r1u3wWfLvpL-lursTEJTmIFbkQbw2wnd0CyCrHDCUj9aGfq8=" rel="nofollow" target="_blank">Longeveron Inc.</a> (NASDAQ: LGVN), a clinical stage biotechnology company developing cellular therapy for life-threatening, rare pediatric and chronic aging-related conditions, today announced that the Company has been granted Small or Medium-sized Enterprise (SME) status by the European Medicines Agency (EMA), which offers significant benefits leading up to and following drug regulatory approval.</p> <p align="justify">The SME program is an initiative by the EMA to address the particular needs of small and medium size companies developing medicinal products in Europe. Companies that are granted SME designation are http://www.streetinsider.com/Press+Releases/Longeveron+Granted+Small+or+Medium-sized+Enterprise+%28SME%29+Status+by+the+European+Medicines+Agency+%28EMA%29/26621607.html Tue, 09 Jun 2026 09:20:00 -0400 A.31066700 LGVN LGVNR O.22422661 O.49866458 http://www.streetinsider.com/Press+Releases/Longeveron+Granted+Small+or+Medium-sized+Enterprise+%28SME%29+Status+by+the+European+Medicines+Agency+%28EMA%29/26621607.html <p align="justify">MIAMI, June 09, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=Svu60lW9WOIDqKjZTubb_1iDhmrd9w281EJUhgRzl1ltTNgv_m3Wp10qSa2r1u3wWfLvpL-lursTEJTmIFbkQbw2wnd0CyCrHDCUj9aGfq8=" rel="nofollow" target="_blank">Longeveron Inc.</a> (NASDAQ: LGVN), a clinical stage biotechnology company developing cellular therapy for life-threatening, rare pediatric and chronic aging-related conditions, today announced that the Company has been granted Small or Medium-sized Enterprise (SME) status by the European Medicines Agency (EMA), which offers significant benefits leading up to and following drug regulatory approval.</p> <p align="justify">The SME program is an initiative by the EMA to address the particular needs of small and medium size companies developing medicinal products in Europe. Companies that are granted SME designation are http://www.streetinsider.com/Press+Releases/Longeveron+Granted+Small+or+Medium-sized+Enterprise+%28SME%29+Status+by+the+European+Medicines+Agency+%28EMA%29/26621607.html Tue, 09 Jun 2026 09:20:00 -0400 A.31066700 LGVN LGVNR O.22422661 O.49866458 http://www.streetinsider.com/Press+Releases/Longeveron+Granted+Small+or+Medium-sized+Enterprise+%28SME%29+Status+by+the+European+Medicines+Agency+%28EMA%29/26621607.html <p align="justify">MIAMI, June 09, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=Svu60lW9WOIDqKjZTubb_1iDhmrd9w281EJUhgRzl1ltTNgv_m3Wp10qSa2r1u3wWfLvpL-lursTEJTmIFbkQbw2wnd0CyCrHDCUj9aGfq8=" rel="nofollow" target="_blank">Longeveron Inc.</a> (NASDAQ: LGVN), a clinical stage biotechnology company developing cellular therapy for life-threatening, rare pediatric and chronic aging-related conditions, today announced that the Company has been granted Small or Medium-sized Enterprise (SME) status by the European Medicines Agency (EMA), which offers significant benefits leading up to and following drug regulatory approval.</p> <p align="justify">The SME program is an initiative by the EMA to address the particular needs of small and medium size companies developing medicinal products in Europe. Companies that are granted SME designation are http://www.streetinsider.com/Press+Releases/Longeveron+Granted+Small+or+Medium-sized+Enterprise+%28SME%29+Status+by+the+European+Medicines+Agency+%28EMA%29/26621607.html Tue, 09 Jun 2026 09:20:00 -0400 A.31066700 LGVN LGVNR O.22422661 O.49866458 http://www.streetinsider.com/Press+Releases/Longeveron+Granted+Small+or+Medium-sized+Enterprise+%28SME%29+Status+by+the+European+Medicines+Agency+%28EMA%29/26621607.html <p align="justify">MIAMI, June 09, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=Svu60lW9WOIDqKjZTubb_1iDhmrd9w281EJUhgRzl1ltTNgv_m3Wp10qSa2r1u3wWfLvpL-lursTEJTmIFbkQbw2wnd0CyCrHDCUj9aGfq8=" rel="nofollow" target="_blank">Longeveron Inc.</a> (NASDAQ: LGVN), a clinical stage biotechnology company developing cellular therapy for life-threatening, rare pediatric and chronic aging-related conditions, today announced that the Company has been granted Small or Medium-sized Enterprise (SME) status by the European Medicines Agency (EMA), which offers significant benefits leading up to and following drug regulatory approval.</p> <p align="justify">The SME program is an initiative by the EMA to address the particular needs of small and medium size companies developing medicinal products in Europe. Companies that are granted SME designation are http://www.streetinsider.com/Press+Releases/Longeveron+Granted+Small+or+Medium-sized+Enterprise+%28SME%29+Status+by+the+European+Medicines+Agency+%28EMA%29/26621607.html Tue, 09 Jun 2026 09:20:00 -0400 A.31066700 LGVN LGVNR O.22422661 O.49866458 http://www.streetinsider.com/Press+Releases/Longeveron+Granted+Small+or+Medium-sized+Enterprise+%28SME%29+Status+by+the+European+Medicines+Agency+%28EMA%29/26621607.html <p align="justify">MIAMI, June 09, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=Svu60lW9WOIDqKjZTubb_1iDhmrd9w281EJUhgRzl1ltTNgv_m3Wp10qSa2r1u3wWfLvpL-lursTEJTmIFbkQbw2wnd0CyCrHDCUj9aGfq8=" rel="nofollow" target="_blank">Longeveron Inc.</a> (NASDAQ: LGVN), a clinical stage biotechnology company developing cellular therapy for life-threatening, rare pediatric and chronic aging-related conditions, today announced that the Company has been granted Small or Medium-sized Enterprise (SME) status by the European Medicines Agency (EMA), which offers significant benefits leading up to and following drug regulatory approval.</p> <p align="justify">The SME program is an initiative by the EMA to address the particular needs of small and medium size companies developing medicinal products in Europe. Companies that are granted SME designation are http://www.streetinsider.com/Press+Releases/Longeveron+Granted+Small+or+Medium-sized+Enterprise+%28SME%29+Status+by+the+European+Medicines+Agency+%28EMA%29/26621607.html Tue, 09 Jun 2026 09:20:00 -0400 A.31066700 LGVN LGVNR O.22422661 O.49866458 http://www.streetinsider.com/Globe+Newswire/Longeveron+Granted+Small+or+Medium-sized+Enterprise+%28SME%29+Status+by+the+European+Medicines+Agency+%28EMA%29/26621607.html <p align="justify">MIAMI, June 09, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=Svu60lW9WOIDqKjZTubb_1iDhmrd9w281EJUhgRzl1ltTNgv_m3Wp10qSa2r1u3wWfLvpL-lursTEJTmIFbkQbw2wnd0CyCrHDCUj9aGfq8=" rel="nofollow" target="_blank">Longeveron Inc.</a> (NASDAQ: LGVN), a clinical stage biotechnology company developing cellular therapy for life-threatening, rare pediatric and chronic aging-related conditions, today announced that the Company has been granted Small or Medium-sized Enterprise (SME) status by the European Medicines Agency (EMA), which offers significant benefits leading up to and following drug regulatory approval.</p> <p align="justify">The SME program is an initiative by the EMA to address the particular needs of small and medium size companies developing medicinal products in Europe. Companies that are granted SME designation are http://www.streetinsider.com/Globe+Newswire/Longeveron+Granted+Small+or+Medium-sized+Enterprise+%28SME%29+Status+by+the+European+Medicines+Agency+%28EMA%29/26621607.html Tue, 09 Jun 2026 09:20:00 -0400 A.31066700 LGVN LGVNR O.22422661 O.49866458 http://www.streetinsider.com/Globe+Newswire/Longeveron+Granted+Small+or+Medium-sized+Enterprise+%28SME%29+Status+by+the+European+Medicines+Agency+%28EMA%29/26621607.html <p align="justify">MIAMI, June 09, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=Svu60lW9WOIDqKjZTubb_1iDhmrd9w281EJUhgRzl1ltTNgv_m3Wp10qSa2r1u3wWfLvpL-lursTEJTmIFbkQbw2wnd0CyCrHDCUj9aGfq8=" rel="nofollow" target="_blank">Longeveron Inc.</a> (NASDAQ: LGVN), a clinical stage biotechnology company developing cellular therapy for life-threatening, rare pediatric and chronic aging-related conditions, today announced that the Company has been granted Small or Medium-sized Enterprise (SME) status by the European Medicines Agency (EMA), which offers significant benefits leading up to and following drug regulatory approval.</p> <p align="justify">The SME program is an initiative by the EMA to address the particular needs of small and medium size companies developing medicinal products in Europe. Companies that are granted SME designation are http://www.streetinsider.com/Globe+Newswire/Longeveron+Granted+Small+or+Medium-sized+Enterprise+%28SME%29+Status+by+the+European+Medicines+Agency+%28EMA%29/26621607.html Tue, 09 Jun 2026 09:20:00 -0400 A.31066700 LGVN LGVNR O.22422661 O.49866458 http://www.streetinsider.com/Globe+Newswire/Longeveron+Granted+Small+or+Medium-sized+Enterprise+%28SME%29+Status+by+the+European+Medicines+Agency+%28EMA%29/26621607.html <p align="justify">MIAMI, June 09, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=Svu60lW9WOIDqKjZTubb_1iDhmrd9w281EJUhgRzl1ltTNgv_m3Wp10qSa2r1u3wWfLvpL-lursTEJTmIFbkQbw2wnd0CyCrHDCUj9aGfq8=" rel="nofollow" target="_blank">Longeveron Inc.</a> (NASDAQ: LGVN), a clinical stage biotechnology company developing cellular therapy for life-threatening, rare pediatric and chronic aging-related conditions, today announced that the Company has been granted Small or Medium-sized Enterprise (SME) status by the European Medicines Agency (EMA), which offers significant benefits leading up to and following drug regulatory approval.</p> <p align="justify">The SME program is an initiative by the EMA to address the particular needs of small and medium size companies developing medicinal products in Europe. Companies that are granted SME designation are http://www.streetinsider.com/Globe+Newswire/Longeveron+Granted+Small+or+Medium-sized+Enterprise+%28SME%29+Status+by+the+European+Medicines+Agency+%28EMA%29/26621607.html Tue, 09 Jun 2026 09:20:00 -0400 A.31066700 LGVN LGVNR O.22422661 O.49866458 http://www.streetinsider.com/Globe+Newswire/Longeveron+Granted+Small+or+Medium-sized+Enterprise+%28SME%29+Status+by+the+European+Medicines+Agency+%28EMA%29/26621607.html <p align="justify">MIAMI, June 09, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=Svu60lW9WOIDqKjZTubb_1iDhmrd9w281EJUhgRzl1ltTNgv_m3Wp10qSa2r1u3wWfLvpL-lursTEJTmIFbkQbw2wnd0CyCrHDCUj9aGfq8=" rel="nofollow" target="_blank">Longeveron Inc.</a> (NASDAQ: LGVN), a clinical stage biotechnology company developing cellular therapy for life-threatening, rare pediatric and chronic aging-related conditions, today announced that the Company has been granted Small or Medium-sized Enterprise (SME) status by the European Medicines Agency (EMA), which offers significant benefits leading up to and following drug regulatory approval.</p> <p align="justify">The SME program is an initiative by the EMA to address the particular needs of small and medium size companies developing medicinal products in Europe. Companies that are granted SME designation are http://www.streetinsider.com/Globe+Newswire/Longeveron+Granted+Small+or+Medium-sized+Enterprise+%28SME%29+Status+by+the+European+Medicines+Agency+%28EMA%29/26621607.html Tue, 09 Jun 2026 09:20:00 -0400 A.31066700 LGVN LGVNR O.22422661 O.49866458 http://www.streetinsider.com/Globe+Newswire/Longeveron+Granted+Small+or+Medium-sized+Enterprise+%28SME%29+Status+by+the+European+Medicines+Agency+%28EMA%29/26621607.html <p align="justify">MIAMI, June 09, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=Svu60lW9WOIDqKjZTubb_1iDhmrd9w281EJUhgRzl1ltTNgv_m3Wp10qSa2r1u3wWfLvpL-lursTEJTmIFbkQbw2wnd0CyCrHDCUj9aGfq8=" rel="nofollow" target="_blank">Longeveron Inc.</a> (NASDAQ: LGVN), a clinical stage biotechnology company developing cellular therapy for life-threatening, rare pediatric and chronic aging-related conditions, today announced that the Company has been granted Small or Medium-sized Enterprise (SME) status by the European Medicines Agency (EMA), which offers significant benefits leading up to and following drug regulatory approval.</p> <p align="justify">The SME program is an initiative by the EMA to address the particular needs of small and medium size companies developing medicinal products in Europe. Companies that are granted SME designation are http://www.streetinsider.com/Globe+Newswire/Longeveron+Granted+Small+or+Medium-sized+Enterprise+%28SME%29+Status+by+the+European+Medicines+Agency+%28EMA%29/26621607.html Tue, 09 Jun 2026 09:20:00 -0400 A.31066700 LGVN LGVNR O.22422661 O.49866458 http://www.streetinsider.com/Press+Releases/Longeveron+to+Present+at+BIO+International+Convention+2026/26603470.html <ul type="disc"><li><em>Company will highlight new and recently published data for stem cell therapy laromsestrocel </em></li><li><em>Focus on potential partnership and strategic opportunities for Hypoplastic Left Heart Syndrome, Alzheimer’s disease, Pediatric Dilated Cardiomyopathy and Aging-related Frailty</em></li><li><em>Corporate presentation Wednesday, June 24</em><em>th</em><em> at 2:15pm PT in Theater 4</em><br/><br/></li></ul> <p align="justify">MIAMI, June 04, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=Bexs0PNCsKK2l0tzTxJxa7uIsmUuJ-YaJdSwMLV8hWITG8n0Vr8SFt-QSt7b4_1lks74E4yAp3jb50oFHaWvmgj2Hc_MY-PEiNT6dodqvGw=" rel="nofollow" target="_blank">Longeveron Inc.</a> (NASDAQ: LGVN), a clinical stage biotechnology company developing cellular therapy for life-threatening, rare pediatric and chronic aging-related conditions, today announced that the Company will participate in the <a target="_blank" href="https://www.globenewswire.com/Tracker?data=TjbIhWRTRtZ6QsGhw14aa35QrdV3JzvuRDmqUnaDcLAU5AzfCFASFuJakjMYPq_IaOccq-nvE4KxTJpsMy8AmKhvgJyFjl_hEV0oofe2ffX_55iyC8RqSuDQmOaKdT58" rel="nofollow" target="_blank">BIO International Convention</a> taking place June 22-25, 2026 http://www.streetinsider.com/Press+Releases/Longeveron+to+Present+at+BIO+International+Convention+2026/26603470.html Thu, 04 Jun 2026 09:15:00 -0400 A.33934625 LGVN LGVNR O.21005812 O.49866458